Cellular miR-130b inhibits replication of porcine reproductive and respiratory syndrome virus *in vitro* and *in vivo*

Liwei Li¹, Fei Gao¹,² Yifeng Jiang¹,² Lingxue Yu³, Yanjun Zhou¹, Hao Zheng³, Wu Tong¹, Shen Yang¹, Tianqi Xia¹, Zehui Qu¹ & Guangzhi Tong¹,²

MicroRNAs (miRNAs) can impact viral infections by binding to sequences with partial complementarity on viral RNA transcripts, usually resulting in the repression of virus replication. In the present study, we identified a potential binding site for miR-130 in the 5′ untranslated region (bps 155-162) of the porcine reproductive and respiratory syndrome virus (PRRSV) genome. We found that the delivery of multiple miR-130 family mimics, especially miR-130b, resulted in inhibition of PRRSV replication *in vitro*. miR-130 was effective in inhibiting the replication of multiple type 2 PRRSV strains, but not against vSHE, a classical type 1 strain. miR-130 over-expression did not induce IFN-α or TNF-α expression in either uninfected or PRRSV-infected porcine alveolar macrophages. Results from luciferase reporter assays indicated that miR-130 directly targeted the PRRSV 5′ UTR. Intranasal inoculation of piglets with miR-130b exhibited antiviral activity *in vivo* and partially protected piglets from an otherwise lethal challenge with HP-PRRSV strain vJX143. Overall, these results demonstrate the importance of the miR-130 family in modulating PRRSV replication and also provide a scientific basis for using cellular miRNAs in anti-PRRSV therapies.

Porcine reproductive and respiratory syndrome (PRRS) causes late term abortions and respiratory disease, particularly in young pigs¹. Porcine reproductive and respiratory syndrome virus (PRRSV), the causative agent of PRRS, causes persistent infection and immunosuppression². PRRSV is one of the most economically important viral pathogens in pigs and the significant economic losses to the swine industry have stimulated searches for new ways to control PRRSV transmission.

MicroRNAs (miRNAs) are endogenous, noncoding, small RNAs that function as gene regulators, most commonly by mediating translational repression or degradation of target mRNAs³. The seed region (2–8 nucleotides at the 5′ end) of an miRNA is commonly considered as the key to exerting its silencing function, most often by binding to the 5′ or 3′ untranslated region (5′- or 3′-UTR) of an mRNA sequence⁴,⁵. There is a growing body of evidence that cellular miRNA-mediated RNAi plays a significant role in the intricate networks of host-virus interactions⁶–¹⁰. For example, miR-122, a liver-specific miRNA, facilitates hepatitis C virus (HCV) replication by binding to the 5′ UTR of the viral genomic RNA¹¹,¹². Let-7c inhibits H1N1 influenza A virus replication by directly targeting the 3′ UTR of viral gene M1 (+) cRNA¹³.

PRRSV has been characterized into two distinct genotypes¹⁴,¹⁵. The 5′ UTR of type 1 and type 2 PRRSV have different lengths (approximately 220 and 190 nucleotides (nt), respectively) and share approximately 60% nucleotide homology¹⁶,¹⁷. Several recent studies suggest a role for miRNA-mediated

¹Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai 200241, P.R. China. ²Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, 225009, P.R. China. Correspondence and requests for materials should be addressed to G.T. (email: gztong@svri.ac.cn)
gene regulation in PRRSV pathogenesis.18–24. Our previous study identified that mir-26a could suppress PRRSV replication by activating the type 1 interferon pathway.23 Here we sought to identify additional antiviral miRNAs by computational analysis of the PRRSV genome. We found that miR-130 family members directly target the 5′ UTR of the PRRSV genome and inhibit viral replication both in vitro and in vivo. Over-expression of miR-130b inhibited multiple type 2 strains in a dose-dependent manner, but had no impact on the replication of type 1 strains. Our study reveals an example of an miRNA that modulates PRRSV replication and also highlights a host factor that could be used for RNAi-mediated antiviral therapeutic strategies.

Results

MiR-130 family members inhibit PRRSV replication. We used ViTa25 to predict miRNA target sites in the genomes of the HP-PRRSV strain vJX143 and the classical PRRSV strain vAPRRS. The results indicated that miR-130 might target bps 155 to 162 in the viral genomic RNA through seed base pairing (Fig. 1A). We aligned the target sequences in 24 representative PRRSV strains, covering two genotype and different virulence. The target region was 100% conserved in 21 type 2 strains, which now circulate in most commercial swine industries throughout the world, but was absent in 3 type 1 strains (Fig. 1B).

Since all members of the same miRNA family4,26 (i.e., miRNAs with the same sequence at nucleotides 2 to 8) share the same predicted targets, we synthesized all the five members of miR-130 family, including miR-130a, miR-130b, miR-301a, miR-301b, and miR-454 (Table 1) based on the mature miRNA sequences annotated in miRBase (http://www.mirbase.org/)27. The first nucleotide at the 5′ end of miR-130 family members, except for miR-454, is C (Table 1) and the C is also complementary to the G in the viral genome (taking miR-130b as an example) (Fig. 1A), suggesting that the binding site length of miR-454 is one nucleotide shorter than that of other members.

We transfected chemically modified miR-130 mimics and mutants (80 nM miRNA) into MARC-145 cells, infected these cells with PRRSV vJX143 at an MOI of 0.01, and then examined virus production and viral gene expression by using virus titer assays and quantitative real-time PCR (qRT-PCR). MARC-145 cells transfected with miR-130 mimics yielded significantly lower PRRSV titers and ORF7 gene expression, as compared with cells transfected with the NC mimic (Fig. 2A,B) at 36 h post-infection. Transfection of miR-130 mutants had no significant impact on ORF7 RNA levels and virus titers in MARC-145 cells (Fig. 2C,D), indicating that the miR-130 family has antiviral activity against PRRSV. miR-130a/b seemed to be more efficient suppressors than miR-301a/b (Fig. 2A–D).

Since the miR-130 family is highly conserved between monkeys and pigs, we conducted the subsequent investigations in PAMs, which are the target cells of PRRSV infection in vivo. We analyzed the growth dynamics of HP-PRRSV isolate vJX143 in PAMs transfected with miR-130 family or NC mimics.
Table 1. Sequences of microRNA (miRNA) mimics and inhibitors used in this study.

| Name             | Sequence (5′—3′)                  |
|------------------|----------------------------------|
| miR-130a (130a)  | CAGUGCAUAUGUAAAAGGGCAU            |
| miR-130b (130b)  | CAGUGCAUAUGGGAAGGGCAU             |
| miR-301a (301a)  | CAGUGCAUAUGUAUGGCAAGGC            |
| miR-301b (301b)  | CAGUGCAUAUGUAUGGCAAGGC            |
| miR-454 (454)    | UAGUGCAUAUGCUUAUGGCUAGGGU         |
| miR-130a-mut (130a-m) | CUCACGUUUGUUAAAAGGGCAU       |
| miR-130b-mut (130b-m) | CUCACGUUUGAUGAAAGGGCAU       |
| miR-301a-mut (301a-m) | CUCACGUUUGAUGUUGUCAAAGC       |
| miR-301b-mut (301b-m) | CUCACGUUUGAUGUUGUCAAAGC       |
| miR-454-mut (454-m) | UUCACGUUUAUGCUUAUGGCUAGGGU     |
| miR-130b inhibitor (130b-inhi) | AUGCCCUUUCAUCAUGCACUG | NC = negative control mimic for 24 h prior to PRRSV strain vJX143 infection at a multiplicity of infection (MOI) of 0.01 for 36 h. Virus titers were expressed as the log TCID₅₀/ml. (E) PRRSV growth in MARC-145 cells transfected with miR-130 family mimics. Culture supernatants were collected at the indicated times and titrated. (F) Immunofluorescence staining against the PRRSV N protein after transfection and PRRSV vJX143 infection. MARC-145 cells or PAMs were fixed at 36 h post-infection and immunostained with the mouse monoclonal SDOW17 antibody against the viral N protein and FITC-conjugated goat anti mouse IgG. Cellular nuclei were counterstained with DAPI (1 mg/ml). Data are the mean ± standard deviation of three independent experiments. Statistical significance was analyzed using t-tests; *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.
and found that miR-130b was the most efficient at suppressing viral growth, as compared with the other four members (Fig. 2E). Viral growth was suppressed about 1,000-fold in PAMs transfected with miR-130b during PRRSV infection after 72 h and about 100-fold in PAMs transfected with miR-454. These data were corroborated using an immunofluorescence assay in which we found that transfecting miR-130b reduced N protein expression in both PAMs and MARC-145 cells (Fig. 2F).

MiR-130b inhibits multiple type 2 strains in a dose-dependent manner, but does not inhibit a type 1 strain. To corroborate our findings above with miR-130b further, MARC-145 cells were transfected with increasing concentrations of miR-130b mimics (20, 40, 80 nM) and then infected with vAPRRS. Both PRRSV growth and ORF7 mRNA levels were inhibited as a function of the dose of miR-130b mimic (Fig. 3A,B). Consistent with this, transfecting the miR-130b mimic also reduced the accumulation of the PRRSV nucleocapsid (N) protein in a dose-dependent manner (Fig. 3C). To exclude the possibility that reduced PRRSV replication was due to potential toxicity of the miR-130b mimic, MARC-145 cells were transfected with the miR-130b mimic at different doses (40 nM, 80 nM, and 160 nM). No appreciable effect of the miR-130b mimic on cellular viability or morphology was observed (data not shown).

The potential target region of miR-130b is 100% conserved in 21 type 2 strains, but is absent in 3 type 1 strains. We further investigated the antiviral activity of miR-130b against three other type 2 PRRSV (vAPRRS, vJX143, vJXM100) strains and a classical type 1 PRRSV strain (vSHE) in MARC-145 cells. Over-expression of the miR-130b mimic reduced virus titers and ORF7 gene expression in the 3 type 2 PRRSV strains, but not in vSHE (Fig. 4A,B). miR-130b had no impact on N protein expression from vSHE (Fig. 4C,D).

MiR-130b does not affect IFN-α and TNF-α mRNA expression in PAMs. Two previous studies implicated miR-130 family members in regulating the innate immune system. Zhang et al. found that miR-130 modulated the NF-κB pathway by targeting TNF-α in cervical cancer cells28. Li et al. showed that miR-130 could upregulate type I IFN and decrease the expression of miR-122 in Huh-7.5.1 cells29. To determine whether miR-130 performed a similar role in PAMs, we analyzed IFN-α and TNF-α expression levels in PAMs transfected with miR-130b mimics or inhibitors. Over-expression of miR-130b failed to increase IFN-α or TNF-α mRNA expression in mock or PRRSV-infected PAMs (Fig. 4E), suggesting that miR-130 does not induce the innate immune response in PAMs.
MiR-130 family members directly target the PRRSV genome. We then determined whether the miR-130 family specifically targets the PRRSV genome to exert its antiviral effect (Fig. 1A). Among 20 different vectors containing various PRRSV cDNA fragments, only the relative luciferase activity driven by pGL3-5UTR was significantly reduced by the miR-130b mimic, as compared with cells transfected with the NC mimic (Fig. 5A). To verify further that the direct target sites (bp 155 to 162) in the viral genomic RNA were involved in the inhibition of PRRSV replication, we generated another reporter construct with mutations at positions corresponding to the miR-130 seed region (pGL3-5UTR-mut; Fig. 5B). All 5 miR-130 family members significantly inhibited the luciferase activity of pGL3-5UTR but did not suppress pGL3-5UTR-mut activity (Fig. 5C). Reciprocally, the 5 miR-130 mutants significantly inhibited the luciferase activity of pGL3-5UTR-mut but did not affect pGL3-5UTR activity (Fig. 5D). Thus, the miR-130 family directly targets the PRRSV genome.

Intranasal delivery of miR-130b exhibits antiviral activity in vivo. Finally, to confirm whether the miR-130 family could be used in therapy, we tested the anti-PRRSV effects of miR-130b in piglets. The rectal temperature of each pig was recorded daily until 21 dpi. Pigs treated with miR-130b did not experience elevated rectal temperatures until 10 dpi, while the temperature of pigs in the NC treatment group rapidly rose to 40°C at 3 dpi (Fig. 6A). Comparison of the mean rectal temperatures of the two groups revealed a temperature about 1°C lower in the miR-130b treatment group, as compared with the NC treatment group (Fig. 6B). The lungs of pigs in the miR-130b treatment group showed fewer pathological changes than piglets in the NC treatment group (Fig. 6C). As a highly virulent strain, vJX143 typically causes 100% mortality by 10 dpi. However, 75% of piglets treated with miR-130b survived to 21 dpi (Fig. 6D). PRRSV RNA copy number was analyzed at 3, 7, 10, 14 and 21 dpi and was found to be about 1,000-fold lower in the miR-130b treatment group, as compared with the NC group (Fig. 6E). Thus, it appears that PRRSV replication in vivo can be controlled by miR-130b.
Discussion

Given the breadth of miRNA-mediated regulation of host-virus interaction, the role of cellular miRNAs in PRRSV infection is of significant interest. In the current study, we found that miR-130 family members were strong inhibitors of PRRSV replication (Figs 1 and 2). Over-expression of miR-130b inhibited the replication of multiple type 2 PRRSV isolates in a dose-dependent manner (Figs 3 and 4). The antiviral activity of miR-130 was attributable to the direct targeting of the PRRSV 5′ UTR, rather than to a stimulation of IFN-α and TNF-α expression (Figs 4 and 5). Intranasal delivery of miR-130b exhibited antiviral activity in vivo and provided partial protection to piglets from an otherwise lethal challenge (Fig. 6).

Many computational and experimental approaches have shown that UTRs are common miRNA targets. Previous studies reported that both miR-181 and miR-23 inhibited PRRSV replication by directly binding to the 3′ UTR of viral genomic and subgenomic RNAs. We found that miR-130 instead targets the 5′ UTR of PRRSV (Fig. 1A). This region is highly conserved among type 2 PRRSV, which now circulates in most commercial swine industries throughout the world, but is absent in type 1 PRRSV (Fig. 1B).

The results from vJX143 growth assays in PAMs showed that miR-130a and miR-130b were more efficient at suppressing viral growth than were miR-301a, miR-301b, and miR-454 (Fig. 2E). The five miR-130 family members share the same seed region (2–8 nt at the 5′ end), but cause different inhibitory effects on PRRSV growth. We found that the first nucleotide at the 5′ end of miR-454 is different from other members (Table 1) and the binding site length of miR-454 is one nucleotide shorter, possibly accounting for the weak inhibition of PRRSV growth by miR-454.

Two previous studies implicated the miR-130 family in regulating the innate immune system by targeting TNF-α in cervical cancer cells and by triggering the type I IFN pathway in the Huh-7.5.1 cell line. By contrast, we found no significant change in either IFN-α and TNF-α expression in PAM cells transfected with miR-130b mimics (Fig. 4E), suggesting the miR-130b antiviral activity is more likely attributable to its direct targeting of viral RNA (Fig. 5). We attributed one reasonable cause of this finding to cell specificity. PAM cells as normal macrophage cells showed different behavior to cancer cells against the miR-130b over-expression. Also one miRNA could commonly modulate hundreds of target genes in mammals due to the short length of binding sites, always 8–10 nucleotides. MiR-130 family still might affect other target genes in PAMs which need further experiments to identify.
MiRNAs are considered to have potential efficacy as antiviral therapeutics. The HP-PRRSV strain can cause high fever, high morbidity, and high mortality in pigs. The intranasal inhalation delivery route has been used in many siRNA-mediated therapies against other respiratory viruses. Guo et al. provided the only direct evidence that therapeutic miR-181c delivery could reduce the severity of infection in pigs infected with HP-PRRSV, but still cause 100% mortality. In our study, intranasal delivery of miR-130b exhibited antiviral activity in vivo and provided partial protection to piglets from an otherwise lethal challenge of vJX143. Developing miR-130b as an antiviral therapeutic approach must be rather limited against those strains that have homology and emergence of viral resistance to the miRNA due to mutations in the target sequence is also possible. However, the animal experiments on miRNAs is opening exciting avenues for understanding host-pathogen interactions and for developing therapeutic approaches to treatment of infectious diseases, viral infections in particular.

Overall, our study demonstrates the importance of the miR-130 family in modulating PRRSV replication and also highlights the therapeutic possibility of using miRNAs to control PRRSV infections.

**Methods**

**Cells and viruses.** MARC-145 (ATCC, Manassas, VA) and baby hamster kidney cells (BHK-21; ATCC CCL10) were cultured as described. Porcine alveolar macrophages (PAMs) were obtained by lung lavage of 4-week-old PRRSV-negative piglets as described previously and maintained at 37°C in RPMI 1640 (Gibco) supplemented with 10% fetal bovine serum (FBS) and penicillin-streptomycin. vJX143 (GenBank accession No. EU708726) is a highly pathogenic PRRSV strain isolated from a swine farm in Jiangxi Province, China, in 2006. vJXM100 (GenBank accession No.GQ475526) was obtained through 100 serial passages of vJX143 in MARC-145 cells. vAPRRS (GenBank accession No. GQ330474) and vSHE (GenBank accession No. GQ461593) were rescued from the infectious cDNA clones pAPRRS and pSHE, respectively. High-titer virus stocks were obtained by infecting MARC-145 cells at low multiplicities of infection (MOIs) and titrated using standard TCID_{50} assays, and then stored at −80°C until use.
**MiRNA target prediction and conservation analysis.** miRNA targets in vJX143 and vAPRRS were predicted using ViTa (http://vita.mbc.nctu.edu.tw/)25. For conservation analysis, we aligned the potential target sequences in 24 representative PRRSV strains, including 21 type 2 strains and 3 type 1 strains collected from GenBank (http://www.ncbi.nlm.nih.gov/GenBank), using MegAlign software 42.

**MiRNA mimics.** miR-130 family mimics (130a, 130b, 301a, 301b, 454) were synthesized by GenePharma (Shanghai, China) as double-stranded 2'-O-methyl-modified RNA oligonucleotides. The sense sequences are listed in Table 1. miR-130 mutants and inhibitors, corresponding seed-mutated miR-130 mimics (130a-m, 130b-m, 301a-m, 301b-m, 454-m), and miR-130b inhibitor (130b-inhi) are also listed in Table 1 (underlined letters are mutated bases). The negative-control (NC) mimic sequence was 5'-uucuccgaacgugucacgutt-3'.

**Transfection of miRNA mimic and viral multi-step growth kinetics.** MiRNA or NC mimics were transfected into PAMs or MARC-145 cells at a concentration of 80 nM (except for dosage experiments) using X-tremeGENE siRNA Transfection Reagent (Roche). Twenty-four hours after transfection, cells were infected with PRRSV. For analysis of PRRSV growth, supernatants (0.1 ml/well) from cell cultures were collected at indicated time points post-infection and titrated in MARC-145 cells by standard TCID50 assay using the method of Reed and Muench 43 for virus quantification.

**IFA and Western blotting.** Indirect immunofluorescence assays (IFA) were performed for detection of nucleocapsid (N) protein in PRRSV infected MARC-145 cells or PAMs pre-transfected with miR-130b or NC mimics23. After a final wash step, cell monolayers were visualized using an Olympus inverted fluorescence microscope. To measure N protein expression in dosage experiments, MARC-145 cells were transfected with miR-130b or NC mimics prior to PRRSV infection, and 48 h later, SDS-PAGE and Western blotting assays were conducted with cell lysates 23.

**RNA isolation and qRT-PCR.** Total intracellular RNA was isolated using TRIzol reagent (Invitrogen) according to the manufacturer’s instructions. PrimeScript™ 1st Strand cDNA Synthesis Kit (Takara) was used for reverse transcription. Quantitative RT-PCR (qPCR) analysis was performed using a Step-one Plus real-time PCR system (Applied Biosystems). The levels of ORF7 RNA, IFN-α and TNF-α mRNA were quantified using a SYBR Premix Ex Taq™ (Takara). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was used as an endogenous control and all primers above are listed in Table 2. For detection of the miR-130b expression, a commercial miRcute miRNA First-Strand cDNA Synthesis and a miRcute miRNA qPCR Detection kit (TIANGEN) were used for reverse transcription and measuring miRNA abundance. The ubiquitously expressed U6 small nuclear RNA (TIANGEN) was used for normalization purpose. All PCR experiments were performed in triplicate and relative expression levels were analyzed using the ΔΔCt method44.

**Luciferase assays.** Twenty pGL3 luciferase reporter plasmids containing different cDNA fragments encompassing the PRRSV genome were cloned downstream of the luciferase ORF23 and used for luciferase assays to test and verify predicted miR-130 target regions in the PRRSV genome. For luciferase reporter assays, subconfluent BHK-21 cells cultured in 12-well plates were co-transfected with 500 ng/well of the indicated reporter plasmid and 100 ng/well of pRL-CMV (as an internal control to normalize

### Table 2. Sequence of oligonucleotide primers used in this study.

| Primer         | Sequence (5′−3′)       |
|----------------|------------------------|
| ORF7-F         | CCCTAGTGACCGGGCCAATTGT |
| ORF7-R         | TCCACGGGCTCTGATTGAA    |
| IFN-α-F        | AGCCAAGCAGGGTCCAAGTG   |
| IFN-α-R        | CTCCAGGTACATCCATGCACCC |
| TNF-α-F        | ACCACGCTCTTGGCCTACGGGC |
| TNF-α-R        | TCCCTCGGCTTGACATTGGCTAC |
| GAPDH-F        | CCTTTCGCTTCCCTACCTGCAAC |
| GAPDH-R        | GACGCCTGCTTCCACCTTCT   |
| JX-F           | CCGAGTCTAGTCACGAGCATG  |
| JX-R           | TTTTCACTAGTCATTCGTC    |
| JX-Probe       | FAM-CTCCCGTGACGTTGACCCAC-TAMRA |
| PGL3-5UTR-F    | GCTCTAGAAGTACGTAATGGTGTGTCCT |
| PGL3-5UTR-mut-R | TACCTGACGGGTTAAGGGTGGAGAGACCGTAAAGGTCACGTTCCTCGGAAGCAAGGTCG |

**Table 2. Sequence of oligonucleotide primers used in this study.**
transfection efficiency (Promega) along with the indicated amount of miR-130b or NC mimic. Cells were lysed 24 h later for determination of firefly luciferase activities using the Lucifirease assay system (Promega). Data are presented as the relative luciferase activities in miR-130b mimic-transfected cells relative to NC mimic-transfected controls and are representative of three independent experiments. To generate a miR-130 target-mutated reporter construct (pGL3-5UTR-mut), mutations at positions corresponding to the miR-130 seed region were introduced using PstI restriction site and mutation PCR. Mutant plasmid (pGL3-5UTR-mut) was confirmed by DNA sequencing and the primer sequences are listed in Table 2. Luciferase activity in BHK-21 cell lysates were determined as described above except that miR-130 family mimics or mutants were cotransfected into cells with two reporter constructs (PGL3-5UTR or pGL3-5UTR-mut).

Animal experiments with intranasal delivery of miR-130b. The animal welfare committee of the Shanghai Veterinary Research Institute approved the animal experiments. The approve ID is SYXK-2011–0116. All animal studies were carried out in accordance with the approved guidelines and blinded to remove investigator bias. Twelve 4-week-old PRRSV-free piglets were obtained and divided randomly into three groups, i.e., four piglets in each group. Each treatment group was housed individually. We administered miR-130b or NC mimic (6 mg per dose) mixed with RNAi-Mate (GenePharma) in Opti-MEM® I (Invitrogen) in a final volume of 2.5 ml intranasally to the piglets, and inoculated intranasally with 3 ml of diluted vJX143 (1 × 105 TCID50) 6 h later, simulating the natural route of PRRSV infection. At 5 day post-infection (dpi), second deliveries of miR-130b or NC mimics were performed using the half dose and same route. The rectal temperature of each piglet was monitored daily until 21 dpi. Viral genomic RNA in serum samples from each piglet was isolated using a QIAprep viral RNA minikit (Qiagen) and viral load was detected at 3, 7, 10, 14, and 21 dpi using one-step RT-PCR. Specific primers for quantitative analysis of viral RNA copies and listed in Table 2.

Statistical analysis. All experiments in figures were performed with at least three independent experiments. The appropriate statistical analyses were used and are presented in each figure legend. A P value of less than 0.05 was considered significant.

References
1. Rosow, K. D. Porcine reproductive and respiratory syndrome. Vet Pathol 35, 1–20 (1998).
2. Chand, R. J., Tribble, B. R. & Rowland, R. R. Pathogenesis of porcine reproductive and respiratory syndrome virus. Carr Opin Virol 2, 256–263 (2012).
3. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297 (2004).
4. Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215–233 (2009).
5. Gottwein, E. & Cullen, B. R. Viral and cellular microRNAs as determinants of viral pathogenesis and immunity. Cell Host Microbe 3, 375–387 (2008).
6. LeeC, C. H. et al. A cellular microRNA mediates antiviral defense in human cells. Science 308, 557–560 (2005).
7. Triboulet, R. et al. Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science 315, 1579–1582 (2007).
8. Zhou, Y., Gao, G., Shi, J. A., Zhou, X. & Wang, X. miRNAs: biogenesis, origin and evolution, functions on virus-host interaction. Cell Physiol Biochem 32, 499–510 (2013).
9. Nathans, R. et al. Cellular microRNA and P bodies modulate host-HIV-1 interactions. Mol Cell 34, 696–709 (2009).
10. Otsuka, M. et al. Hypersusceptibility to vesicular stomatitis virus infection in Dicer1-deficient mice is due to impaired miR24 and miR93 expression. Immunity 27, 123–134 (2007).
11. Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M. & Sarnow, P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309, 1577–1581 (2005).
12. Jopling, C. L. Targeting microRNA-122 to Treat Hepatitis C Virus Infection. Viruses 2, 1382–1393 (2010).
13. Ma, Y. J. et al. Cellular microRNA let-7c inhibits M1 protein expression of the H1N1 influenza A virus in infected human lung epithelial cells. J Cell Mol Med 16, 2539–2546 (2012).
14. Forsberg, R. Divergence time of porcine reproductive and respiratory syndrome virus subtypes. Mol Biol Evol 22, 2131–2134 (2005).
15. Hanada, K., Suzuki, Y., Nakane, T., Hirose, O. & Gojobori, T. The origin and evolution of porcine reproductive and respiratory syndrome viruses. Mol Biol Evol 22, 1024–1031 (2005).
16. Lu, J. et al. A 5′-proximal stem-loop structure of 5′ untranslated region of porcine reproductive and respiratory syndrome virus genome is key for virus replication. Virol J 8, 172 (2011).
17. Gao, F. et al. Replacement of the heterologous 5′ untranslated region allows preservation of the fully functional activities of type 2 porcine reproductive and respiratory syndrome virus. Virology 439, 1–12 (2013).
18. Wang, D. et al. MiR-125b reduces porcine reproductive and respiratory syndrome virus replication by negatively regulating the NF-kappaB pathway. PLoS One 8, e55838 (2013).
19. Zhang, Q. et al. MicroRNA-23 inhibits PRRSV replication by directly targeting PRRSV RNA and possibly by upregulating type I interferons. Virology 450, 182–195 (2014).
20. Wu, J. et al. MiR-506 inhibits PRRSV replication in MARC-145 cells via CD151. Mol Cell Biochem 394, 275–281 (2014).
21. Guo, X. K. et al. Increasing expression of microRNA 181 inhibits porcine reproductive and respiratory syndrome virus replication and has implications for controlling virus infection. J Virol 87, 1159–1171 (2013).
22. Gao, L. et al. MicroRNA 181 suppresses porcine reproductive and respiratory syndrome virus (PRRSV) infection by targeting PRRSV receptor CD163. J Virol 87, 8808–8812 (2013).
23. Li, L. et al. Host miR-26a suppresses replication of porcine reproductive and respiratory syndrome virus by upregulating type I interferons. Virus Res 195, 86–94 (2015).
24. Jia, X. et al. Cellular microRNA miR-26a suppresses replication of porcine reproductive and respiratory syndrome virus by activating innate antiviral immunity. Sci Rep 5, 10651 (2015).
25. Hsu, P. W., Lin, L. Z., Hsu, S. D., Hsu, J. B. & Huang, H. D. ViTa: prediction of host microRNAs targets on viruses. Nucleic Acids Res 35, D381–385 (2007).
26. tenOever, B. R. RNA viruses and the host microRNA machinery. Nat Rev Microbiol 11, 169–180 (2013).
27. Griffiths-Jones, S., Saini, H. K., van Dongen, S. & Enright, A. J. miRBase: tools for microRNA genomics. Nucleic Acids Res 36, D154–158 (2008).
28. Zhang, J. et al. NF-kappaB-modulated miR-130a targets TNF-alpha in cervical cancer cells. J Transl Med 12, 155 (2014).
29. Li, S. et al. MicroRNA-130a inhibits HCV replication by restoring the innate immune response. J Viral Hepat 21, 121–128 (2014).
30. Tong, G. Z. et al. Highly pathogenic porcine reproductive and respiratory syndrome, China. Emerg Infect Dis 13, 1434–1436 (2007).
31. Costa Mdo, C. et al. Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease. Mol Ther 21, 1899–1908 (2013).
32. Zhou, Y. J. et al. Highly virulent porcine reproductive and respiratory syndrome virus emerged in China. Transbound Emerg Dis 55, 152–164 (2008).
33. Bitko, V., Musiyenko, A., Shulyayeva, O. & Barik, S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 11, 50–55 (2005).
34. Zhang, W. et al. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med 11, 56–62 (2005).
35. Palliser, D. et al. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 439, 89–94 (2006).
36. Gao, F. et al. Cis-acting structural element in 5′ UTR is essential for infectivity of porcine reproductive and respiratory syndrome virus. Virus Res 163, 108–119 (2012).
37. Yuan, S. & Wei, Z. Construction of infectious cDNA clones of PRRSV: separation of coding regions for nonstructural and structural proteins. Sci China C Life Sci 51, 271–279 (2008).
38. Wensvoort, G. et al. Mystery swine disease in The Netherlands: the isolation of Lelystad virus. Vet Q 13, 121–130 (1991).
39. Lv, J., Zhang, J., Sun, Z., Liu, W. & Yuan, S. An infectious cDNA clone of a highly pathogenic porcine reproductive and respiratory syndrome virus variant associated with porcine high fever syndrome. J Gen Virol 89, 2075–2079 (2008).
40. Wang, X. et al. Development of a differentiable virus via a spontaneous deletion in the nsp2 region associated with cell adaptation of porcine reproductive and respiratory syndrome virus. Virus Res 171, 150–160 (2013).
41. Tian, D., Zheng, H., Zhang, R., Zhuang, J. & Yuan, S. Chimeric porcine reproductive and respiratory syndrome viruses reveal full function of genotype 1 envelope proteins in the backbone of genotype 2. Virology 412, 1–8 (2011).
42. Clewley, J. P. & Arnold, C. MEGALIGN. The multiple alignment module of LASERGENE. Methods Mol Biol 70, 119–129 (1997).
43. Reed, L. J. & Muench, H. A simple method of estimating fifty percent endpoints. The American Journal of Hygiene 27, 493–497 (1938).
44. Bookout, A. L., Cammins, C. L., Mangelsdorf, D. J., Pesola, J. M. & Kramer, M. F. High-throughput real-time quantitative reverse transcription PCR. Curr Protoc Mol Biol 73, 15.18.11–15.18.28 (2006).

Acknowledgements
The study was supported by the grants from the National Basic Research Program (973 Plan) (no. 2014CB542700), the National Natural Science foundation of China (no. 31100121, no. 31302098, no. 3130140), the National Key Technology Support Program (2015BAD12B01-1), and the National Science Foundation of Shanghai (no. 11JC1415200).

Author Contributions
This study was conceived and designed by G.T. and L.L. All authors participated in the experiments. L.L. wrote the main manuscript text and prepared figures. F.G., Y.J., L.Y., Y.Z., H.Z. and W.T. prepared the manuscript. S.Y., T.X. and Z.Q. performed animal experiments. All authors reviewed the manuscript.

Additional Information
Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Li, L. et al. Cellular miR-130b inhibits replication of porcine reproductive and respiratory syndrome virus in vitro and in vivo. Sci. Rep. 5, 17010; doi: 10.1038/srep17010 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/